Advancing Pharmacist-Led Care in Chronic Myeloid Leukemia: Bridging Knowledge and Practice Gaps to Optimize Tyrosine Kinase Inhibitor Management and Patient Adherence

Program Description

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the unregulated growth of myeloid cells. The introduction of tyrosine kinase inhibitors (TKIs) has transformed CML into a manageable chronic condition with improved long-term outcomes. However, in real-world community oncology practice, challenges persist in optimizing therapy due to complex dosing considerations, access and affordability barriers, and the need for ongoing management of adverse effects. This session will equip oncology pharmacists with practical, evidence-based strategies to support patients receiving TKI therapy in the community setting. Faculty will emphasize the pharmacist’s role in patient education, setting expectations for long-term therapy, and proactively identifying and managing adverse effects to support adherence and persistence. Participants will gain insights into counseling patients at therapy initiation, monitoring for and mitigating toxicities, navigating access challenges, and collaborating with the care team to optimize outcomes. Furthermore, the session will highlight the oncology pharmacist’s pivotal role in leveraging electronic monitoring and medication management systems to track treatment persistence, mitigate adverse effects, and support the development of protocols to safely transition eligible patients toward treatment-free remission.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: .75 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply evolving clinical evidence and guideline updates to individualize frontline tyrosine kinase inhibitor (TKI) selection and sequencing in chronic myeloid leukemia (CML), incorporating patient comorbidities, BCR::ABL1 mutation status, tolerability, and cost considerations
• Investigate strategies to monitor and manage TKI-associated adverse effects and overcome adherence barriers, utilizing evidence-based dose adjustments, patient education, and supportive interventions
• Employ emerging technologies in clinical practice to enhance treatment adherence in patients with CML

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-26-110-H01-P. The activity is available for CE credit through May 12, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Marlo Blazer, PharmD, BCOP has no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP, Daphne Davis, PharmD, BCOP; Emily Tyler; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Allison Morse, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose: Advisory Board: Bristol Myers Squibb, Daiichi Sankyo

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:

ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:

www.pharmacytimes.org/terms